B. Riley Lowers Lantheus (NASDAQ:LNTH) Price Target to $122.00

Lantheus (NASDAQ:LNTH) had its target price cut by B. Riley from $127.00 to $122.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. B. Riley’s price objective suggests a potential upside of 24.86% from the stock’s current price. B. Riley also issued estimates for Lantheus’ Q3 2025 earnings at $1.51 EPS.

LNTH has been the subject of a number of other reports. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. JMP Securities reissued a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. Finally, Truist Financial raised their price target on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $129.43.

Lantheus Trading Down 1.2 %

Shares of LNTH opened at $97.71 on Friday. The company has a market capitalization of $6.69 billion, a price-to-earnings ratio of 16.26 and a beta of 0.38. The stock has a 50 day moving average of $92.67 and a 200 day moving average of $96.58. Lantheus has a 12 month low of $57.92 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. As a group, equities research analysts predict that Lantheus will post 6.01 earnings per share for the current year.

Insider Transactions at Lantheus

In related news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 64,109 shares of company stock worth $6,110,806. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC grew its holdings in shares of Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after acquiring an additional 2,610,118 shares during the period. Farallon Capital Management LLC boosted its stake in Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after purchasing an additional 435,445 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Lantheus during the 4th quarter valued at $36,183,000. Finally, Groupama Asset Managment purchased a new stake in Lantheus during the 3rd quarter valued at $439,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.